COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 4 FDA records to the applicant name Abbott Diabetes Care, Inc.. It includes 2 original PMA approvals. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Sep 23, 2016 to Sep 1, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MDS appears in 2 of the 4 linked filings. The collection spans 2 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P150021, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 3 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 1360 S. Loop Rd., Alameda, CA, 94502. Recorded on P150021/S061, decision dated Sep 1, 2026.
Device categories in this collection
Sensor, Glucose, Invasive; Sensor, Glucose, Invasive, Non-Adjunctive, Factory-Calibrated, User-Initiated.
Changes described in PMA records
The record for P150021/S061 describes a 30-day notice under reason code "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The reported change is "addition of a secondary supplier and manufacturer for subcomponents and subassemblies for sensor kits." The filing identifies the sensor as a component of the FreeStyle Libre 14-day and FreeStyle Libre Pro Flash Glucose Monitoring Systems, so the stated scope concerns sensor-kit subcomponents and subassemblies rather than the complete systems.
The identifier links this notice to prior PMA P150021 as a supplement, not a new approval of any whole system. The decision code OK30 and date 2026-09-01 appear in the supplied record, but the text gives no details on which subcomponents or subassemblies, which supplier or manufacturer, or what evidence supported the change; it is a sponsor-stated purpose, not independent proof of safety or clinical effectiveness.
FDA approval-order wording
addition of a secondary supplier and manufacturer for subcomponents and subassemblies for sensor kits. The sensor is a component of the FreeStyle Libre 14-day and FreeStyle Libre Pro Flash Glucose Monitoring Systems
Sep 1, 2026 · 30-Day NoticeP160030/S058 is a 30-day notice recorded with decision OK30 on 2026-09-01 for the FreeStyle Libre Flash Glucose Monitoring System. The reported change is the addition of a secondary supplier and manufacturer for subcomponents and subassemblies for sensor kits. The sensor is a component of the FreeStyle Libre 14-day and FreeStyle Libre Pro systems; the source gives no further detail on which subcomponents, which supplier, or which manufacturing steps are involved.
Because the identifier and supplement type establish it, this is a supplement to PMA P160030, not an original approval of the whole system, and it does not alter the parent approval. The field label categorizes the reason as a process change involving a manufacturer, sterilizer, packager or supplier. The stated purpose is administrative and manufacturing-related; it is not independent evidence of sensor safety or clinical effectiveness, and no new indication or clinical use should be inferred.
FDA approval-order wording
addition of a secondary supplier and manufacturer for subcomponents and subassemblies for sensor kits. The sensor is a component of the FreeStyle Libre 14-day and FreeStyle Libre Pro Flash Glucose Monitoring Systems
Sep 1, 2026 · 30-Day NoticeFDA’s recorded scope: Approval for the Freestyle Libre Flash Glucose Monitoring System. The FreeStyle Libre Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device indicated for the management of diabetes in persons age 18 and older. It is designed to replace blood glucose testing for diabetes treatment decisions.The System detects trends and tracks patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the System readings should be based on the glucose trends and several sequential readings over time. The System is intended for single patient use and requires a prescription.
Sep 27, 2017FDA approved PMA P150021 on September 23, 2016, for the FreeStyle Libre Pro Flash Glucose Monitoring System from Abbott Diabetes Care, Inc. The approval covers a professional continuous glucose monitoring device for detecting trends and tracking patterns in adults 18 and older with diabetes. The system is intended for health care professionals, requires a prescription, and does not require user calibration with blood glucose values.
Sensor readings are made available to patients only through consultation with a health care professional. The statement describes the system as aiding detection of glucose excursions above or below the desired range to support therapy adjustments, with interpretation based on trends and patterns over time using available reports. The source does not include independent proof of safety or clinical effectiveness beyond this stated purpose.
FDA approval-order wording
The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The System is intended for use by health care professionals and requires a prescription. Readings from the FreeStyle Libre Pro Sensor are only made available to patients through consultation with a health care professional. The System does not require user calibration with blood glucose values.The FreeStyle Libre Pro System aids in the detection of glucose level excursions above or below the desired range, facilitating therapy adjustments. Interpretation of the FreeStyle Libre Pro Flash Glucose Monitoring System readings should be based on the trends and patterns analyzed through time using the reports available.
Sep 23, 2016Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.